Meforal Xr (Metformin Hydrochloride)

Metformin acts primarily by inhibiting hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity through activation of the AMP‑activated protein kinase (AMPK) pathway, thereby lowering circulating glucose levels.

The dosage of Meforal Xr is individualized by the prescribing clinician based on the patient’s glycaemic targets, renal function, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of metformin during pregnancy and lactation is not fully established. It should only be used if the potential benefit justifies the potential risk, and the decision must be made by a qualified healthcare professional.

To request Meforal Xr, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is the first‑line therapy for type 2 diabetes because it improves insulin sensitivity without causing hypoglycaemia, unlike sulfonylureas or insulin. It is also weight‑neutral or modestly weight‑reducing, which distinguishes it from many other glucose‑lowering agents.

Store Meforal Xr at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed.

Meforal Xr is taken orally, usually with meals to minimise gastrointestinal upset. The tablets should be swallowed whole with a glass of water and not crushed or chewed.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition. Early signs include unexplained fatigue, muscle pain, rapid breathing, or abdominal discomfort, and patients should seek immediate medical attention if they occur.

Meforal Xr is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those with conditions predisposing to hypoxia such as severe heart failure.